Solanezumab

From Wikipedia, the free encyclopedia - View original article

Solanezumab ?
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetBeta amyloid
Clinical data
Legal statusInvestigational
Identifiers
CAS number955085-14-0 N
ATC codeNone
UNII5D6PWO0333 YesY
KEGGD10058 N
Chemical data
FormulaC6396H9922N1712O1996S42 
Mol. mass144.1 kDa
 N (what is this?)  (verify)
 
Jump to: navigation, search
Solanezumab ?
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetBeta amyloid
Clinical data
Legal statusInvestigational
Identifiers
CAS number955085-14-0 N
ATC codeNone
UNII5D6PWO0333 YesY
KEGGD10058 N
Chemical data
FormulaC6396H9922N1712O1996S42 
Mol. mass144.1 kDa
 N (what is this?)  (verify)

Solanezumab (proposed INN) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector[1] for patients with Alzheimer's disease.[2][3]

It binds to the amyloid-β peptides that make up the protein plaques seen in the brains of people with the disease.

2012 results of the EXPEDITION 1 & 2 phase 3 clinical trials were only mildly encouraging.[4][5][6] but were said to be the "first evidence that targeting the amyloid cascade can slow the progression of disease.”[7]

References[edit]

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. ^ ClinicalTrials.gov NCT00749216 Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
  3. ^ ClinicalTrials.gov NCT00905372 Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)
  4. ^ "Lilly's Solanezumab Slows Down Alzheimer's Progression". 9 Oct 2012. 
  5. ^ Solanezumab Did it actually work
  6. ^ "Eli Lilly’s solanezumab faces grim prospects of attaining conditional FDA approval in mild Alzheimer’s". 4 Sep 2012. 
  7. ^ "ALZHEIMER'S DRUG SLOWS MEMORY LOSS BY ONE THIRD". 10 Oct 2012.